Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

318
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
173
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

153
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
153
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Neoadjuvant tislelizumab (anti-PD-1 antibody) plus chemotherapy in patients with advanced epithelial ovarian cancer: the exploratory NAIVE trial.

Signal transduction and targeted therapy·2026
Same author

Orientation dependence of the magnetic phase diagram of Yb<sub>2</sub>Ti<sub>2</sub>O<sub>7</sub>.

Physical review. B·2026
Same author

Real-World Multicenter Study on the Effectiveness of Dolutegravir Plus Lamivudine in Treatment-Naive People Living with HIV with Baseline HIV-1 RNA > 500,000 Copies/mL.

Infectious diseases and therapy·2026
Same author

A large-scale retrospective analysis reveals the fungal pathogen spectrum across diverse clinical specimens using metagenomic next-generation sequencing.

Frontiers in cellular and infection microbiology·2026
Same author

The Global Burden and Trends of Premenopausal Breast Cancer by Modifiable Lifestyle Factors From 1990 to 2021 With Prediction Until 2039.

Global health, epidemiology and genomics·2026
Same author

Interfacial Electronic Modulation Redirects Anodic Radical Chemistry for Selective C─C Bond Cleavage in Electro-Oxidative Lignin Depolymerization.

Angewandte Chemie (International ed. in English)·2026

相关实验视频

Updated: Jun 26, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.1K

基于因克雷的药物降低了2型糖尿病患者前列腺癌的发病率:一个聚合分析分析.

Yuxiang Lin1, Guangyong Xu1, Liangyu Li1

  • 1Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Medicine
|May 17, 2024
PubMed
概括

用于治疗2型糖尿病的以因克雷为基础的药物,可显著降低前列腺癌风险35%. 这包括类似葡萄糖素的-1受体激动剂和二二酶-4抑制剂,表明潜在的预防作用.

更多相关视频

Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.6K

相关实验视频

Last Updated: Jun 26, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.1K
Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

19.6K

科学领域:

  • 内分泌学和糖尿病研究研究
  • 瘤学和癌症预防 癌症预防

背景情况:

  • 基于因克雷的药物被广泛用于2型糖尿病管理.
  • 这些抗糖尿病药物与前列腺癌 (PCa) 发病率之间的潜在联系需要调查.
  • 有限的现实世界数据存在于基于英克雷丁的药物和PCa风险之间的关联.

研究的目的:

  • 为了评估基于隐素的药物对前列腺癌发病率的影响.
  • 具体评估葡萄糖类-1 (GLP-1) 受体激活剂和二二酶-4 (DPP-4) 抑制剂对PCa风险的影响.

主要方法:

  • 在PubMed,Embase和Cochrane图书馆数据库中进行系统的文献搜索,截至2023年9月.
  • 来自7项高质量研究 (2项RCT,5项队列研究) 的数据的元分析,涉及1,165,738名患者.
  • 使用柯克兰手册和纽卡斯尔-太华尺度 (NOS) 进行质量评估.

主要成果:

  • 基于因克雷的药物与前列腺癌风险显著减少35%有关 (RR 0.17-0.49,P=0.0006).
  • 小组分析显示GLP-1受体激动剂降低了62%的风险 (RR 0.45-0.85,P=0.003).
  • DPP-4 抑制剂显示了降低风险的趋势 (RR 0.46-1.12,P=0.14).

结论:

  • 基于因克雷的药物与2型糖尿病患者的前列腺癌发病率较低有关.
  • 这些抗糖尿病药物可能对前列腺癌的发展具有保护作用.
  • 进一步的研究可能会阐明这种观察到的关联背后的机制.